Tandem Diabetes Care Files 8-K

TL;DR

Tandem Diabetes Care filed an 8-K on May 10, 2024, detailing material agreements and other corporate events.

AI Summary

On May 10, 2024, Tandem Diabetes Care, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing indicates significant corporate events and the release of financial information for Tandem Diabetes Care, Inc.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report detailing corporate events and financial statements, not indicating immediate financial distress or significant new risks.

Key Numbers

• 12400 High Bluff Drive — Business Address (Principal executive offices location)
• 92130 — ZIP Code (Principal executive offices ZIP code)
• 858-366-6900 — Phone Number (Registrant's telephone number)

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• May 10, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices
• 001-36189 (company_id) — SEC File Number

FAQ

From the Filing

0001438133-24-000088.txt : 20240516 0001438133-24-000088.hdr.sgml : 20240516 20240516163554 ACCESSION NUMBER: 0001438133-24-000088 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240510 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240516 DATE AS OF CHANGE: 20240516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 24956169 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20240510.htm 8-K tndm-20240510 0001438133 FALSE 0001438133 2024-05-10 2024-05-10   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 1.01 Entry into a Material Definitive Agreement. On May 10, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) and Unomedical a/s, a Danish corporation and a subsidiary of the ConvaTec Group (“Unomedical”), entered into Amendment Number 1 (“Amendment 1”) to the Distributor Agreement, dated as of January 14, 2022, between the Company and Unomedical, under which Unomedical manufactures, tests, sterilizes and packs all of the infusion sets under the Compa